189 related articles for article (PubMed ID: 17343804)
1. Targeted, gene-directed enzyme prodrug therapies to tackle diversity and aggression of late stage prostate cancer.
Khatri A; Russell PJ
Discov Med; 2007 Feb; 7(37):39-45. PubMed ID: 17343804
[TBL] [Abstract][Full Text] [Related]
2. Novel gene-directed enzyme prodrug therapies against prostate cancer.
Russell PJ; Khatri A
Expert Opin Investig Drugs; 2006 Aug; 15(8):947-61. PubMed ID: 16859396
[TBL] [Abstract][Full Text] [Related]
3. Recent progress in gene-directed enzyme prodrug therapy: an emerging cancer treatment.
Both GW
Curr Opin Mol Ther; 2009 Aug; 11(4):421-32. PubMed ID: 19649987
[TBL] [Abstract][Full Text] [Related]
4. Clinical potential of gene-directed enzyme prodrug therapy to improve radiation therapy in prostate cancer patients.
Vajda A; Marignol L; Foley R; Lynch TH; Lawler M; Hollywood D
Cancer Treat Rev; 2011 Dec; 37(8):643-54. PubMed ID: 21481534
[TBL] [Abstract][Full Text] [Related]
5. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
Roy P; Waxman DJ
Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390
[TBL] [Abstract][Full Text] [Related]
6. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer.
Connors TA
Gene Ther; 1995 Dec; 2(10):702-9. PubMed ID: 8750009
[TBL] [Abstract][Full Text] [Related]
7. Recent developments in gene-directed enzyme prodrug therapy (GDEPT) for cancer.
Niculescu-Duvaz I; Cooper RG; Stribbling SM; Heyes JA; Metcalfe JA; Springer CJ
Curr Opin Mol Ther; 1999 Aug; 1(4):480-6. PubMed ID: 11713763
[TBL] [Abstract][Full Text] [Related]
8. Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT).
Niculescu-Duvaz I; Friedlos F; Niculescu-Duvaz D; Davies L; Springer CJ
Anticancer Drug Des; 1999 Dec; 14(6):517-38. PubMed ID: 10834273
[TBL] [Abstract][Full Text] [Related]
9. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives.
Greco O; Dachs GU
J Cell Physiol; 2001 Apr; 187(1):22-36. PubMed ID: 11241346
[TBL] [Abstract][Full Text] [Related]
10. Strategies for enzyme/prodrug cancer therapy.
Xu G; McLeod HL
Clin Cancer Res; 2001 Nov; 7(11):3314-24. PubMed ID: 11705842
[TBL] [Abstract][Full Text] [Related]
11. Gene-directed enzyme prodrug therapy with carboxylesterase enhances the anticancer efficacy of the conditionally replicating adenovirus AdDelta24.
Oosterhoff D; Pinedo HM; Witlox MA; Carette JE; Gerritsen WR; van Beusechem VW
Gene Ther; 2005 Jun; 12(12):1011-8. PubMed ID: 15729367
[TBL] [Abstract][Full Text] [Related]
12. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
Hwang C; Sanda MG
Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
[TBL] [Abstract][Full Text] [Related]
13. Targeted prodrug approaches for hormone refractory prostate cancer.
Aloysius H; Hu L
Med Res Rev; 2015 May; 35(3):554-85. PubMed ID: 25529338
[TBL] [Abstract][Full Text] [Related]
14. New strategies for the medical treatment of prostate cancer.
Isaacs JT
BJU Int; 2005 Dec; 96 Suppl 2():35-40. PubMed ID: 16359437
[TBL] [Abstract][Full Text] [Related]
15. Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniques.
Eaton JD; Perry MJ; Todryk SM; Mazucco RA; Kirby RS; Griffiths JR; Dalgleish AG
Gene Ther; 2001 Apr; 8(7):557-67. PubMed ID: 11319623
[TBL] [Abstract][Full Text] [Related]
16. Gene-directed enzyme prodrug therapy (GDEPT)--recognizing the present limitations of gene therapy for the treatment of cancer.
Knox RJ
Curr Opin Investig Drugs; 2001 Jun; 2(6):835-8. PubMed ID: 11572666
[No Abstract] [Full Text] [Related]
17. Prodrugs in cancer chemotherapy.
Connors TA; Knox RJ
Stem Cells; 1995 Sep; 13(5):501-11. PubMed ID: 8528099
[TBL] [Abstract][Full Text] [Related]
18. Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors.
Djeha AH; Thomson TA; Leung H; Searle PF; Young LS; Kerr DJ; Harris PA; Mountain A; Wrighton CJ
Mol Ther; 2001 Feb; 3(2):233-40. PubMed ID: 11237680
[TBL] [Abstract][Full Text] [Related]
19. Gene therapy for prostate cancer.
Gdor Y; Timme TL; Miles BJ; Kadmon D; Thompson TC
Expert Rev Anticancer Ther; 2002 Jun; 2(3):309-21. PubMed ID: 12113054
[TBL] [Abstract][Full Text] [Related]
20. Combining gene and immunotherapy for prostate cancer.
Young JG; Green NK; Mautner V; Searle PF; Young LS; James ND
Prostate Cancer Prostatic Dis; 2008; 11(2):187-93. PubMed ID: 17726452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
